Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > About us > Strategic Collaborations Strategic Collaborations Strategic collaborations Crescendo is leveraging the unique benefits of the Humabody® platform through ongoing partnerships with leading biopharmaceutical companies and research institutions within immuno-oncology and other disease areas. Takeda Pharmaceutical Company Ltd Crescendo signed a global, strategic, multi-target collaboration and license agreement with Takeda Pharmaceutical Company Ltd in October 2016. The collaboration is for the development and commercialisation of Humabody therapeutics for the treatment of cancer indications with high unmet need. The targets, selected by Takeda, include both immuno-oncology (IO) modulators and Humabody drug conjugates (HDCs) and was expanded in 2019 to include the development of Humabody VH domains for inclusion in Takeda’s CAR-T therapies. Zai Lab The exclusive, worldwide licence agreement between Crescendo and Zai Lab, signed in 2018, enables the development of an innovative, topically-delivered Humabody therapeutic for inflammatory indications. Zai Lab’s first clinical study for ZL-1102 (CB001) is in psoriasis. Cancer Research UK Crescendo and Cancer Research UK signed a Clinical Development Partnership in 2020 to develop CB213. CB213 targets T cell exhaustion in cancers of high unmet medical need. Cancer Research UK’s Centre for Drug Development will sponsor and fund a future Phase I clinical trial for CB213, in patients with solid tumours. Orano Med Orano Med is a nuclear biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (²¹²Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative approach for developing therapeutics capable of destroying cancer cells through alpha particle emission, while limiting the impact on nearby healthy cells. In March 2020, Crescendo signed a pre-clinical collaboration agreement with Orano Med to exemplify the benefit of Humabody VH for precise targeting of Orano Med’s Alpha Therapy. Astellas Crescendo’s entered into an agreement with Astellas for discovery and development of novel Humabody therapeutics focused on immune checkpoint inhibitors. Crescendo successfully delivered all the relevant targets. Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok

Careers Contact Us Home About us Our Pipeline Our Science Partnering News & Events Crescendo > About us > Investors Investors Investors Humabody® and Multibody® are registered trademarks of Crescendo Biologics Ltd. Meditrina Building 260, Babraham Research Campus, Cambridge, CB22 3AT Cambridge Web Design